Rasagiline (Azilect) vs Safinamide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: MAO-B · full Parkinson's Disease pipeline

Rasagiline (Azilect)

Marketed by Teva Pharmaceutical Industries and partners

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT01479530 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled trial with 321 participants, with 158 assigned to placebo and 163 to rasagiline. The primary clinical endpoint—change in daily OFF time—favored rasagiline and was statistically significant (p=0.0228).

Reported efficacy

Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 4, 8, 12, and 16): Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 4, 8, 12, and 16): Azilect® -1.25 hours (Standard Error 0.16) vs Placebo -0.76 hours (Standard Error 0.16) (met)

Result source: NCT01479530

Safinamide · Xadago

Marketed by Supernus Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT00605683 · Phase 3 · completed

The study was randomized and double-blind, included 679 participants, and compared two safinamide doses with placebo. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2027 · NCT07761936 (registry estimate)

Reported efficacy

Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time (At baseline and Week 16): Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time (At baseline and Week 16): Safinamide -1.93 Hours (Standard Deviation 2.556) vs Placebo -0.88 Hours (Standard Deviation 2.543) (met)

Result source: NCT03881371

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointRasagiline (Azilect)Safinamide
OFF time, change-1.3 vs -0.8−0.5 vs placebowk 16 · n 158NCT01479530
1 other result
-1.9 vs -0.9−1 vs placebowk 16 · n 151NCT03881371
ON time without troublesome dyskinesia, change—Not posted · NCT00203034—Not posted · NCT00643045
UPDRS Part III, change—Not posted · NCT00203034—Not posted · NCT00643045
MDS-UPDRS Part II, change0.1 vs 2.3−2.2 vs placebo1 mg · wk 26 · n 116NCT02337725
2 other results
  • -0.3 vs 1.0 1 mg · wk 26 · n 126 · Phase 2/3 · secondary NCT02337738
  • -0.3 vs 1.0 0.5 mg · wk 26 · n 132 · Phase 2/3 · secondary NCT02337738
—Not posted · NCT00643045

OFF time, change

Rasagiline (Azilect)
-1.3 vs -0.8−0.5 vs placebowk 16 · n 158NCT01479530
1 other result
Safinamide
-1.9 vs -0.9−1 vs placebowk 16 · n 151NCT03881371

ON time without troublesome dyskinesia, change

Rasagiline (Azilect)
—Not posted · NCT00203034
Safinamide
—Not posted · NCT00643045

UPDRS Part III, change

Rasagiline (Azilect)
—Not posted · NCT00203034
Safinamide
—Not posted · NCT00643045

MDS-UPDRS Part II, change

Rasagiline (Azilect)
0.1 vs 2.3−2.2 vs placebo1 mg · wk 26 · n 116NCT02337725
2 other results
  • -0.3 vs 1.0 1 mg · wk 26 · n 126 · Phase 2/3 · secondary NCT02337738
  • -0.3 vs 1.0 0.5 mg · wk 26 · n 132 · Phase 2/3 · secondary NCT02337738
Safinamide
—Not posted · NCT00643045
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Rasagiline (Azilect): 6 of 6 rows · Safinamide: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRasagiline (Azilect)
Rows use multiple source trials
Safinamide
Rows use multiple source trials
MDS-UPDRS Part III
absolute change · score
No placebo or comparator arm
-7.6 score @ 52wk1 mga,b,c,d
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-1.7 score @ 18wk100 mga,b,c,d
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
OFF Time
absolute change · hours
No placebo or comparator arm
-0.89 hours @ 52wk1 mga,b,c,d
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-0.8 hours @ 18wk100 mga,b,c,d
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
Dropout rate
7.4%e
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 7 more results
12.1%
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
27%1 mg
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
11.6%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence
15.5%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
6.8%1 mg
NCT02337725 · Phase 3 · registry result, not featured evidence
20.2%1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
22.4%0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
10.5%f
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
19.4%100 mg
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
17.4%
NCT03841604 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
3.7%e
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 7 more results
10.6%
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
20.7%1 mg
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
2.1%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence
2.9%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
—1 mg
NCT02337725 · Phase 3 · registry result, not featured evidence
16.3%1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
13.4%0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
5.2%f
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
6%100 mg
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
8.7%
NCT03841604 · Phase 4 · registry result, not featured evidence
Serious AEs
4.3%e
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 7 more results
7.6%
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
17.6%1 mg
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.2%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence
5.1%1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
3.4%1 mg
NCT02337725 · Phase 3 · registry result, not featured evidence
7.8%1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
7.5%0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
5.3%f
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
2%100 mg
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
0%
NCT03841604 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
e
dyskinesia 6.7% (placebo 7.6%)
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 7 more results
dyskinesia 12.1% (placebo 7.6%)
dizziness 6.1% (placebo 1.5%)
dyspnoea 6.1% (placebo 0%)
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
1 mg
fall 16.7%
nasopharyngitis 14%
dyskinesia 10.8%
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1 mg
nasopharyngitis 17.9%
fall 6.3%
contusion 5.3%
NCT02337751 · Phase 3 · registry result, not featured evidence
1 mg
nasopharyngitis 26.5%
fall 9.4%
eczema 7.7%
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
1 mg
nasopharyngitis 15.4% (placebo 15.1%)
fall 5.1% (placebo 5.6%)
NCT02337725 · Phase 3 · registry result, not featured evidence
1 mg
dyskinesia 15.5% (placebo 7.1%)
nasopharyngitis 14.7% (placebo 9.2%)
fall 13.2% (placebo 5.7%)
NCT02337738 · Phase 2/3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 18% (placebo 9.2%)
fall 9.8% (placebo 5.7%)
dyskinesia 8.3% (placebo 7.1%)
NCT02337738 · Phase 2/3 · registry result, not featured evidence
f
dyskinesia 11.9% (placebo 3.9%)
back pain 6% (placebo 3.9%)
dizziness 6% (placebo 6.5%)
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
100 mg
overdose 6.5%
dyskinesia 5.5%
covid-19 2.5%
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
constipation 6.5% (placebo 0%)
back pain 4.3% (placebo 0%)
dyskinesia 4.3% (placebo 0%)
NCT03841604 · Phase 4 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context differs: monotherapy versus add on.
  4. dAssessment timepoints differ: 52 weeks versus 18 weeks.
  5. ePopulation comparability has not been reviewed for 5 of these studies.
  6. fPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Rasagiline (Azilect)

CGI-I 3.15 vs 3.56 placebo score @ 16wk
absolute value · score
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 1 more result
3.05 vs 3.35 placebo score @ 18wk
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
UPDRS-ADL -2.21 vs -1.2 placebo score @ 16wk
absolute change · score
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 1 more result
-0.57 vs 0.13 placebo score @ 18wk
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
UPDRS Motor -3.34 vs -1.75 placebo score @ 16wk
absolute change · score
NCT01479530 · Phase 3 · Parkinson's Disease · phase 3
show 1 more result
-2.87 vs -1.52 placebo score @ 18wk
NCT01268891 · Phase 3 · Parkinson's Disease · phase 3
MDS-UPDRS Part II 0 score @ 52wk1 mg
absolute change · score
No placebo or comparator arm
NCT02337764 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Parts II III -2.8 score @ 52wk1 mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT02337751 · Phase 3 · registry result, not featured evidence
show 1 more result
-2.8 score @ 52wk1 mg
NCT02337751 · Phase 3 · registry result, not featured evidence · combination
MDS-UPDRS Parts II III -4.52 vs 1.87 placebo score @ 26wk1 mg
absolute change · score
NCT02337725 · Phase 3 · registry result, not featured evidence
MDS-UPDRS Part I 0.18 vs 0.98 placebo score @ 26wk1 mg
absolute change · score
NCT02337725 · Phase 3 · registry result, not featured evidence
MDS-UPDRS Part II 0.13 vs 2.32 placebo score @ 26wk1 mg
absolute change · score
NCT02337725 · Phase 3 · registry result, not featured evidence
show 2 more results
-0.3 vs 0.97 placebo score @ 26wk1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
-0.3 vs 0.97 placebo score @ 26wk0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
MDS-UPDRS Part III -4.47 vs -0.48 placebo score @ 26wk1 mg
absolute change · score
NCT02337725 · Phase 3 · registry result, not featured evidence
show 2 more results
-5.65 vs -3.5 placebo score @ 26wk1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
-5.24 vs -3.5 placebo score @ 26wk0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
OFF-time Change -1.35 vs -0.51 placebo per day @ 26wk1 mg
absolute change · per day
NCT02337738 · Phase 2/3 · registry result, not featured evidence
show 3 more results
-1.4 vs -0.5 placebo per day @ 26wk1 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
-1.11 vs -0.51 placebo per day @ 26wk0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
-0.99 vs -0.5 placebo per day @ 26wk0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence
PDQ-39 Summary Index -1 vs 2.84 placebo score @ 26wk1 mg
absolute change · score
NCT02337738 · Phase 2/3 · registry result, not featured evidence
show 1 more result
0.33 vs 2.84 placebo score @ 26wk0.5 mg
NCT02337738 · Phase 2/3 · registry result, not featured evidence

Safinamide

Pain NRS 0 vs 0 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
-1.6 vs -0.8 placebo score @ 16wk
NCT03841604 · Phase 4 · registry result, not featured evidence
-1.6 vs -0.8 placebo score @ 16wk
NCT03841604 · Phase 4 · registry result, not featured evidence
Daily "ON" Time 1.3 vs 0.51 placebo hours @ 16wk
absolute change · hours
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
On-time No Troublesome Dyskinesia 1.3 vs 0.39 placebo hours @ 16wk
absolute change · hours
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS Total -12.3 vs -5.8 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS Part II ADL -2.7 vs -1.2 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS Part III (Motor -8.2 vs -3.7 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
CGI-S 3.6 vs 3.8 placebo score @ 16wk
absolute value · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
3.4 vs 3.5 placebo score @ 16wk
NCT03841604 · Phase 4 · registry result, not featured evidence
CGI-C 3 vs 3.4 placebo score @ 16wk
absolute value · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
3.4 vs 3.5 placebo score @ 16wk
NCT03841604 · Phase 4 · registry result, not featured evidence
PDQ-39 -6.42 vs -2.67 placebo score @ 16wk
absolute change · score
NCT03881371 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
PDQ-39 Summary Index -2.7 score @ 18wk100 mg
absolute change · score
No placebo or comparator arm
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
MDS-UPDRS (Part IV -0.7 score @ 18wk100 mg
absolute change · score
No placebo or comparator arm
NCT05312632 · Phase 4 · registry result, not featured evidence · add on
KPPS -1.5 score @ 18wk100 mg
absolute change · score
No placebo or comparator arm
NCT05312632 · Phase 4 · registry result, not featured evidence · add on

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rasagiline (Azilect)'s landscape · Safinamide's landscape